Neurotech Partners
Neurotech

이벤트 개요

이 컨퍼런스는 뇌 및 신경계의 새로운 치료법과 진단법 개발에 참여하고 있는 투자자, 기업가, 기업 임원, 연구자 등이 한자리에 모여 소속 조직과 업계의 미래에 대해 생각하는 국제적 포럼입니다.

컨퍼런스에서는 뉴로테크놀러지 업계의 최신 동향에 관한 기조 강연, 기업의 최첨단 기술 발표, 주요 중개연구 프로젝트에 대한 보고, 패널 디스커션 등이 예정되어 있으며, 뉴로테크놀러지 관련 토픽을 폭넓게 다룹니다.

PRELIMINARY AGENDA


5월 31일(수)


7:30 등록, 아침식사

8:30 기조 강연, 2017년 뉴로테크놀러지 업계의 상황
Alison Fenney, Executive Director, Neurotechnology Industry Organization
Harry Tracy, President, NI Research
James Cavuoto, Editor & Publisher, Neurotech Reports

9:00 뉴로테크놀러지 분야에 대한 투자에 관한 패널 디스커션
A diverse panel of private, public and strategic investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are the benefits and risks of business models in devices, pharmaceuticals, diagnostics and information technology? What are today's deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?
Moderator: Josh Pinto, Vice President, CNS, Credit Suisse

Panelists: Andy Schwab, Managing Partner, 5AM Ventures
Joseph Sum, Analyst, EcoR1 Capital
Ilan Zipkin, Senior Investment Director, Takeda Venture Partners
Heath Lukatch, Partner and Managing Director, TPG Biotech

10:00 전시회장 휴식시간, 포스터 발표 관람

10:40 알츠하이머병과 인지장애 치료
Globally, the population continues to age and the number of dementia patients keeps expanding. Ongoing efforts to develop disease modifying therapies have been plagued with failures. What new avenues are being pursued to address the growing global need? Will novel diagnostics allow us to initiate treatments earlier? What non-pharmacological options are in development?

Panelists: Casey Lynch, CEO, Cortexyme
Mark Gurney, CEO, Tetra Discovery Partners
Eyal Baror, CEO and President, Neuronix

11:40 신경장애성 통증과 간질에 대한 치료법 개발 동향
Ongoing research is revealing new pharmaceutical and device options to treat pain and epilepsy. Novel therapeutic modalities aim to decrease side effects and improve efficacy in treatment-resistant populations for epilepsy and neuropathic pain. What are the novel devices in this space? How are side effects being addressed?

Panelists: Alex Ni, CTO, Avertus
Alan Mock, Chief Commercial Officer, Algostim

12:40 오찬회

13:55 조직 내외 연구개발
Big pharma, big medtech and large biotech companies collaborate with smaller companies and academic institutions on a variety of projects. How can opportunities be spotted? What are current areas of interest? Where are companies focusing internal versus external resources? What opportunities exist for research and development collaborations with academic groups, research institutes, and platform companies?
Moderator: Jay Kranzler, CEO, Regenovation

Panelists: Ryan Westphal, Director, Search and Evaluation, Neuroscience, Eli Lilly and Company
Thorsten Melcher, Senior Director, New Ventures, Johnson & Johnson Innovation
Anne Pianca, Director, R&D Neuromodulation, Boston Scientific
Rivka Kreitman, Senior Vice President & Head, Global Search and Evaluation, Teva Pharmaceuticals

14:55 전시회장 휴식시간, 포스터 발표 관람

15:35 중추신경계 질환용 약제 및 기기 개발의 전략
Intelligent trial design, fundraising, business development and product life cycle development strategy is critical to the success of any neurotech venture. An insider panel will discuss specific tactics for improving drug and device development to navigate a path to approval and reimbursement.

Panelist: Tina Soulis, General Manager, Neuroscience Trials Australia

16:35 신규 기업 소개
Submissions to be accepted in February

17:35 전시회장 환영 리셉션, 포스터 발표 관람

18:30 첫째날 종료


6월 1일(목)


7:30 등록, 아침식사

8:30 뉴로테크놀러지 분야에서의 라이선스와 인수
Neurology is projected to be medtech's fastest-growing segment in the next five years. Pharma companies are adapting to the current environment with targeted deal-making. Overall all, big pharma, biotech and medtech are increasingly looking to smaller firms to provide innovative product candidates to fill pipelines. What are current trends in strategic alliances and inlicensing? What are priority indications and requirements for licensing deals? Which companies are active in deal-making?
Moderator: Christine de los Reyes, Vice President, Strategic Planning & Business Development, Alopexx Enterprises

Panelists: Susan Lin, Vice President, New Ventures & Business Development, LivaNova
Jeff Calcagno, New Ventures, Johnson & Johnson Innovation

9:30 파킨슨병 등의 운동장애
Current treatments for movement disorders can improve functioning but suffer from side effects and "off" period especially as the disease progresses. What are the latest advances in movement disorders? What is in the pipeline to address side effects and other issues specific to this class? Can disease modifying treatments alter the course of disease? Can diagnostics improve treatment?
Moderator: John Reppas, Director, Public Policy, Neurotechnology Industry Organization

Panelist: Kyle Gano, Vice President, Business Development, Neurocrine Biosciences

10:30 전시회장 휴식시간, 포스터 발표 관람

11:15 차세대 정신의학
Schizophrenia, anxiety, depression, addiction, ADHD and other psychiatric illnesses represent a large portion of the neurotech market. What are the most promising next-generation treatments? How will devices and diagnostics change the treatment landscape?
Moderator: Manuel Lopez Figueroa, Partner, Bay City Capital

Panelists: Yaron Daniely, President & CEO, Alcobra
Robert Linke, President & CEO, Embera NeuroTherapeutics

12:15 오찬회

13:30 뉴로테크놀러지 분야의 미개척 영역
In this session we will hear from companies on the cutting edge. Novel neurostimulation devices for a variety of indications, software solutions for neuropsychiatric markets, and new neurodiagnostic tools are on the brink of success. Which are the most exciting next-generation products and companies? How are they addressing unmet needs in neurotech?
Moderator: Imran Eba, Partner, Action Potential Venture Capital, GSK

Panelists: Corianna Lathan, CEO, Anthrotronix
Laura Tyler Perryman, CEO and Co-Founder, StimWave
Will Rosellini, CEO, Nexeon Medi

14:30 신경치료 영양학
Nutrition is at the core of novel approaches for disease prevention and treatments. What is neurotherapeutic nutrition? How can nutrition address CNS disorders? What companies are focusing on developing neurotherapeutic nutrition approaches? What hurdles will these companies face?
Moderator: Bram Goorden, Vice President, Global Head, Nestle Health Science

Panelists: John Andrews, CEO, Ketogen
Joan Fallon, CEO, Curemark
Jill C. Milne, CEO, Catabasis

15:30 휴식시간

15:45 희귀질환의 표적화
Orphan disorders are a hot area of investment due to perceived benefits with regulatory agencies, ready access to patients, and premium pricing. Hear from companies developing treatments for ALS, lysosomal storage disorders, Huntington's, and more. What are the strategies to succeed in addressing a smaller market? Are R&D approaches different than for other indications?

Panelist: Tim Miller, CEO, Abeona Therapeutics

16:45 다발성 경화증 치료의 새로운 전략
Therapies directed at novel targets, more specific immune modulators and trophic factors are in development for multiple sclerosis. What are the promising treatments in development? How are indication-specific hurdles being addressed? What novel approaches are being pursued?

Panelists: Maurice Zauderer, CEO, Vaccinex
Marie Wesselhoft, President and Co-Founder, MSDx

17:45 컨퍼런스 폐막

* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.

Choose your language
Traditional Chinese
Simplified Chinese
Japanese
English

Catalog
Demographics

 NIO


 

View All Sponsors

  

국제컨퍼런스
Giievent


메일링 서비스
메일링 서비스